Inozyme Pharma (NASDAQ:INZY) Announces Earnings Results, Misses Estimates By $0.07 EPS

Inozyme Pharma (NASDAQ:INZY) issued its quarterly earnings results on Tuesday. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07), Zacks reports.

Inozyme Pharma Stock Up 0.2 %

Shares of Inozyme Pharma stock traded up $0.01 during trading on Friday, hitting $4.39. 14,657 shares of the stock traded hands, compared to its average volume of 481,808. The stock has a market cap of $271.55 million, a P/E ratio of -3.20 and a beta of 1.52. The company has a debt-to-equity ratio of 0.38, a quick ratio of 14.05 and a current ratio of 14.05. Inozyme Pharma has a twelve month low of $2.69 and a twelve month high of $7.80. The company has a fifty day moving average price of $4.91 and a two-hundred day moving average price of $5.24.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on INZY shares. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price target on shares of Inozyme Pharma in a research note on Tuesday. Wells Fargo & Company began coverage on Inozyme Pharma in a research report on Thursday, May 30th. They set an “overweight” rating and a $14.00 price objective for the company. Wedbush restated an “outperform” rating and set a $15.00 price objective on shares of Inozyme Pharma in a research report on Tuesday. Finally, HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of Inozyme Pharma in a research report on Thursday. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Inozyme Pharma has an average rating of “Buy” and a consensus price target of $16.00.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.